Vitrafy Life Sciences (ASX:VFY) Enters US Cell and Gene Therapy Market via Charter Medical

Sonal Goyal

02 September 2026 11:00 AM AEST

Vitrafy Life Sciences (ASX:VFY) Enters US Cell and Gene Therapy Market via Charter Medical

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Vitrafy has agreed to install its cryopreservation ecosystem, comprising the Guardion freezing unit and LifeChain software, at Charter Medical's North Carolina Innovation Hub
This marks Vitrafy's first agreement in the cell and gene therapy sector and its first deployment in North America
The agreement spans an initial six-month term with deployment occurring in the second half of FY2027, and no Revenue will be generated during that initial term
Charter Medical has more than 30 years' experience supplying the CDMO and cell and gene therapy Manufacturing sectors and is ISO 13485/NSAI certified and FDA registered

Vitrafy Life Sciences Ltd (ASX:VFY) has announced an agreement with Charter Medical, LLC to deploy its cryopreservation ecosystem at Charter Medical's Innovation Hub in Winston-Salem, North Carolina. The company said the agreement marks its first entry into the U.S. cell and gene therapy market and its first deployment in North America.

About the Agreement

Under the agreement, Vitrafy will install one Guardion cryopreservation freezing unit alongside its LifeChain software platform at Charter Medical's Innovation Hub, where the technology will support cryopreservation and freeze-curve optimisation studies for Charter Medical's cell and gene therapy customers. The Guardion unit is designed to deliver controlled, reproducible freeze profiles across a range of cell lines, while LifeChain is designed to capture processing data to help develop improved cryopreservation protocols.

The agreement spans an initial six-month term, with deployment expected to occur in the second half of FY2027. The company confirmed no revenue will be generated during this initial term. Vitrafy said the deployment demonstrates the applicability of its ecosystem beyond blood-market activities, extending into a segment where the value of preserved biomaterial is high and cryopreservation performance is a recognised requirement for many manufacturers.

About Charter Medical

Charter Medical, LLC designs and manufactures standard and custom single-use technologies for the advanced therapy, bioprocessing and blood management markets. The company has more than 30 years' experience and is an ISO 13485/NSAI certified and FDA registered supplier to biopharmaceutical companies. Charter's Innovation Hub, established in 2024, is located in downtown Winston-Salem's Innovation Quarter, an area anchored by the Wake Forest University School of Medicine and home to a concentration of regenerative medicine and cell therapy activity. The hub houses laboratory space dedicated to single-use freezing, transportation and protection studies supporting the biopharmaceutical industry's cold chain, and Charter Medical is part of the Solesis family of companies.

Conclusion

Vitrafy's agreement with Charter Medical extends the company's cryopreservation technology into the U.S. cell and gene therapy market for the first time, though the initial six-month term will not generate revenue and any broader commercial relationship will depend on the outcomes of the evaluation work undertaken during deployment. With deployment scheduled for the second half of FY2027, the agreement provides Vitrafy with a foothold in a sector the company considers has high-value applications for its cryopreservation ecosystem.

FAQs

Q: What has Vitrafy agreed with Charter Medical?

A: Vitrafy will install its Guardion cryopreservation freezing unit and LifeChain software platform at Charter Medical's North Carolina Innovation Hub to support cryopreservation studies for cell and gene therapy customers.

Q: Is this Vitrafy's first agreement in this sector?

A: Yes, the company said this is its first agreement in cell and gene therapy and its first deployment in North America.

Q: Will the agreement generate revenue immediately?

A: No, the agreement spans an initial six-month term with deployment in the second half of FY2027, and the company confirmed no revenue will be generated during that initial term.

Q: Who is Charter Medical?

A: Charter Medical is a more than 30-year-old, ISO 13485/NSAI certified and FDA registered manufacturer of single-use technologies for the advanced therapy, bioprocessing and blood management markets.

Q: What technology does Vitrafy's ecosystem include?

A: The ecosystem comprises the Guardion cryopreservation freezing unit and the LifeChain cloud-based software platform, designed to deliver controlled freeze profiles and capture processing data.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.